17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial

OBJECTIVE: To examine responder rates and vasomotor symptom-free days with oral 17β-estradiol/progesterone (E2/P4; TX-001HR) versus placebo in the REPLENISH trial. METHODS: REPLENISH (NCT01942668) was a phase 3, randomized, double-blind, placebo-controlled, multicenter trial, evaluating single, oral...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Menopause
Autori principali: Kaunitz, Andrew M., Bitner, Diana, Constantine, Ginger D., Bernick, Brian, Graham, Shelli, Mirkin, Sebastian
Natura: Artigo
Lingua:Inglês
Pubblicazione: Lippincott Williams & Wilkins 2020
Soggetti:
Original Studies
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7709918/
https://ncbi.nlm.nih.gov/pubmed/32740481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/GME.0000000000001615
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi